Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication

International Journal of Cancer

Volumn 129, Issue 6, 2011, Pages 1503-1510

  Fu, Xinping ^a   Tao, Lihua ^a   Rivera, Armando ^a   Zhang, Xiaoliu ^a  

^a University of Houston   (United States)

Author keywords

herpes simplex virus; mTOR; oncolytic virus; rapamycin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BACO 1; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE B INHIBITOR IV; PROTEIN KINASE B INHIBITOR V; RAPAMYCIN; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR; TUMOR CELL; VIROGENESIS; VIROTHERAPY; VIRUS REPLICATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SIMPLEXVIRUS; SIROLIMUS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960924757     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25808     Document Type: Article

References (21)

1. Russell SJ, Peng KW,. Viruses as anticancer drugs. Trends Pharmacol Sci 2007; 28: 326-33. (Pubitemid 47016683)
2. Liu TC, Galanis E, Kirn D,. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-17. (Pubitemid 46189539)
3. Thorne SH, Hermiston T, Kirn D,. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 2005; 32: 537-48. (Pubitemid 41772681)
4. Everts B, van der Poel HG,. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005; 12: 141-61. (Pubitemid 40205096)
5. Rabkin SD, Driever PH,. Replication-competent herpes simplex virus vectors for cancer therapy. In:, Driever PH, Rabkin SD, eds. Replication-competent viruses for cancer therapy. Basel: Karger, 2001. 1-45.
6. Shah AC, Price KH, Parker JN, Samuel SL, Meleth S, Cassady KA, Gillespie GY, Whitley RJ, Markert JM,. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. J Virol 2006; 80: 7308-15. (Pubitemid 44092553)
7. Li H, Zeng Z, Fu X, Zhang X,. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res 2007; 67: 7850-5. (Pubitemid 47281380)
8. Stanford MM, Barrett JW, Nazarian SH, Werden S, McFadden G,. Oncolytic virotherapy synergism with signaling inhibitors: rapamycin increases myxoma virus tropism for human tumor cells. J Virol 2007; 81: 1251-60. (Pubitemid 46167846)
9. Alain T, Lun X, Martineau Y, Sean P, Pulendran B, Petroulakis E, Zemp FJ, Lemay CG, Roy D, Bell JC, Thomas G, Kozma SC, et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci USA 2010; 107: 1576-81.
10. Mishra R, Miyamoto M, Yoshioka T, Ishikawa K, Matsumura Y, Shoji Y, Ichinokawa K, Itoh T, Shichinohe T, Hirano S, Kondo S,. Adenovirus- mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo. Int J Oncol 2009; 34: 1231-40.
11. Moorman NJ, Shenk T,. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol 2010; 84: 5260-9.
12. Fu X, Tao L, Jin A, Vile R, Brenner M, Zhang X,. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus provides potent synergistic anti-tumor effect. Mol Ther 2003; 7: 748-54. (Pubitemid 36790251)
13. Fu X, Tao L, Cai R, Prigge J, Zhang X,. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther 2006; 13: 882-90.
14. Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RCJ, Zhang X,. Effective Therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane-fusion mechanisms. Clin Cancer Res 2003; 9: 2727-33. (Pubitemid 36842119)
15. Fu X, Zhang X,. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002; 62: 2306-12. (Pubitemid 34411709)
16. Nakamori M, Fu X, Pettaway CA, Zhang X,. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 2004; 60: 53-60. (Pubitemid 38669229)
17. Fu X, Tao L, Zhang X,. An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells. Gene Ther 2007; 14: 1218-25. (Pubitemid 47224553)
18. Hou G, Zhang Q, Wang L, Liu M, Wang J, Xue L,. mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. Cancer Lett 2010; 290: 248-54.
19. van Beusechem VW, Mastenbroek DC, van den Doel PB, Lamfers ML, Grill J, Wurdinger T, Haisma HJ, Pinedo HM, Gerritsen WR,. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther 2003; 10: 1982-91. (Pubitemid 37337074)
20. Spear PG,. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 2004; 6: 401-10. (Pubitemid 38488933)
21. Costa-Mattioli M, Sonenberg N,. RAPping production of type I interferon in pDCs through mTOR. Nat Immunol 2008; 9: 1097-9.